SG10202101501PA - PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS - Google Patents
PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERSInfo
- Publication number
- SG10202101501PA SG10202101501PA SG10202101501PA SG10202101501PA SG10202101501PA SG 10202101501P A SG10202101501P A SG 10202101501PA SG 10202101501P A SG10202101501P A SG 10202101501PA SG 10202101501P A SG10202101501P A SG 10202101501PA SG 10202101501P A SG10202101501P A SG 10202101501PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- pparγ agonist
- blood cancers
- cancers
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376749P | 2016-08-18 | 2016-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202101501PA true SG10202101501PA (en) | 2021-03-30 |
Family
ID=61197183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101501PA SG10202101501PA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
| SG11201901320WA SG11201901320WA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901320WA SG11201901320WA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Country Status (12)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 |
| CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
| WO2020243058A1 (en) * | 2019-05-30 | 2020-12-03 | Coherus Biosciences, Inc. | Compositions and methods to treat cancer |
| JP2022104747A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗ウイルス剤 |
| JP2022104746A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗がん剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3018186B1 (ja) * | 1999-03-09 | 2000-03-13 | 大阪大学長 | 抗炎症剤、単球系細胞の増殖抑制剤 |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| JP2010265216A (ja) * | 2009-05-14 | 2010-11-25 | Takeda Chem Ind Ltd | 複素環化合物 |
| EP2950798B1 (en) * | 2013-01-30 | 2021-05-12 | Intekrin Therapeutics, Inc. | Ppar-gamma agonist for treatment of multiple sclerosis |
| JP7349790B2 (ja) * | 2016-06-08 | 2023-09-25 | サポート－ヴェンチャー ゲゼルシャフト ミット ベシュレンクター ハフトゥング | がんを治療するための薬学的組み合わせ |
-
2017
- 2017-08-18 MX MX2019001979A patent/MX2019001979A/es unknown
- 2017-08-18 SG SG10202101501PA patent/SG10202101501PA/en unknown
- 2017-08-18 EA EA201990512A patent/EA201990512A1/ru unknown
- 2017-08-18 KR KR1020197007705A patent/KR20190064573A/ko not_active Ceased
- 2017-08-18 JP JP2019530367A patent/JP2019524888A/ja active Pending
- 2017-08-18 EP EP17842202.8A patent/EP3500268A4/en not_active Withdrawn
- 2017-08-18 US US16/326,018 patent/US20210379049A1/en not_active Abandoned
- 2017-08-18 CN CN201780063382.4A patent/CN110461329A/zh active Pending
- 2017-08-18 BR BR112019003130-8A patent/BR112019003130A2/pt not_active IP Right Cessation
- 2017-08-18 WO PCT/US2017/047578 patent/WO2018035446A1/en unknown
- 2017-08-18 SG SG11201901320WA patent/SG11201901320WA/en unknown
- 2017-08-18 AU AU2017313839A patent/AU2017313839A1/en not_active Abandoned
- 2017-08-18 CA CA3034258A patent/CA3034258A1/en active Pending
-
2022
- 2022-06-06 JP JP2022091309A patent/JP2022116304A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019001979A (es) | 2019-09-19 |
| CA3034258A1 (en) | 2018-02-22 |
| AU2017313839A1 (en) | 2019-03-07 |
| BR112019003130A2 (pt) | 2019-05-21 |
| EA201990512A1 (ru) | 2019-08-30 |
| WO2018035446A1 (en) | 2018-02-22 |
| CN110461329A (zh) | 2019-11-15 |
| US20210379049A1 (en) | 2021-12-09 |
| JP2019524888A (ja) | 2019-09-05 |
| EP3500268A1 (en) | 2019-06-26 |
| JP2022116304A (ja) | 2022-08-09 |
| SG11201901320WA (en) | 2019-03-28 |
| KR20190064573A (ko) | 2019-06-10 |
| EP3500268A4 (en) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266847A (en) | Cancer treatment methods involving tigit-binding agents | |
| ZA202006746B (en) | Methods of treatment | |
| ZA201708448B (en) | Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia | |
| IL250677A0 (en) | Cancer treatment using anti-nkg2a agents | |
| ZA201703585B (en) | Combination immunotherapy approach for treatment of cancer | |
| IL285077A (en) | Compounds for the treatment of cancer | |
| SG10201801562PA (en) | Combination method for treatment of cancer | |
| IL262005A (en) | Methods of treating cancer in children | |
| IL247267A0 (en) | Methods for the treatment of vascular invasive cancers | |
| EP3227686A4 (en) | Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer | |
| SG10202101501PA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| EP3134528A4 (en) | Multiple targeted rnai for the treatment of cancers | |
| GB201717945D0 (en) | Method for treatment of cancer | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| EP3389670A4 (en) | METHODS OF TREATING BREAST CANCER | |
| SG10202101500WA (en) | PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS | |
| EP3102940A4 (en) | Anti-metalloprotease antibody for diagnosis and treatment of cancers | |
| HK40011080A (en) | Ppary agonist for treatment of blood cancers | |
| EP3125878A4 (en) | Methods of treating breast cancer | |
| HK40012509A (en) | Combination immunotherapies for treatment of cancer | |
| GB201702139D0 (en) | Methods of cancer treatment | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201604621D0 (en) | Treatment of cancer | |
| GB201604293D0 (en) | Treatment of cancer |